Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 3
2011 1
2012 2
2013 1
2014 1
2015 1
2016 1
2017 1
2019 1
2020 1
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. Kappos L, et al. N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20. N Engl J Med. 2010. PMID: 20089952 Free article. Clinical Trial.
Posterior Reversible Encephalopathy Syndrome With Concurrent Nephrotic Syndrome in a Patient Treated With Pazopanib for Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature.
Miaris N, Maltezou M, Papaxoinis G, Visvikis A, Samantas E. Miaris N, et al. Among authors: maltezou m. Clin Genitourin Cancer. 2017 Feb;15(1):e99-e103. doi: 10.1016/j.clgc.2016.08.005. Epub 2016 Aug 10. Clin Genitourin Cancer. 2017. PMID: 27601362 Review. No abstract available.
A Prospective, Observational, Cohort Study to Assess the Efficacy and Safety of Prolonged-Release Fampridine in Cognition, Fatigue, Depression, and Quality of Life in Multiple Sclerosis Patients: The FAMILY Study.
Mitsikostas DD, Doskas T, Gkatzonis S, Fakas N, Maltezou M, Papadopoulos D, Gourgioti R, Mitsias P. Mitsikostas DD, et al. Among authors: maltezou m. Adv Ther. 2021 Mar;38(3):1536-1551. doi: 10.1007/s12325-020-01606-5. Epub 2021 Feb 2. Adv Ther. 2021. PMID: 33528792 Free PMC article.
Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece.
Dardiotis E, Perpati G, Borsos M, Nikolaidis I, Tzanetakos D, Deretzi G, Koutlas E, Kilidireas C, Mitsikostas DD, Hadjigeorgiou G, Grigoriadis N; AURELIO investigators. Dardiotis E, et al. Neurol Ther. 2022 Sep;11(3):1375-1390. doi: 10.1007/s40120-022-00384-2. Epub 2022 Jul 13. Neurol Ther. 2022. PMID: 35829919 Free PMC article.
Acute Dystonia in a Patient with 22q11.2 Deletion Syndrome.
Kontoangelos K, Maillis A, Maltezou M, Tsiori S, Papageorgiou CC. Kontoangelos K, et al. Among authors: maltezou m. Ment Illn. 2015 Sep 30;7(2):5902. doi: 10.4081/mi.2015.5902. eCollection 2015 Sep 30. Ment Illn. 2015. PMID: 26605035 Free PMC article.
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Radue EW, et al. Arch Neurol. 2012 Oct;69(10):1259-69. doi: 10.1001/archneurol.2012.1051. Arch Neurol. 2012. PMID: 22751847 Clinical Trial.
15 results